NEPH (Nephros) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


NEPH Nephros Inc NEPH
63 GF Score
Price $3.30
GF Value $2.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Tariff Resilience Score?

Nephros NEPH -2.93% 63 Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.88 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Nephros ranks better than 91.03% on this metric.

Nephros has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Nephros has Nephros has a balanced import/export profile with some manufacturing in tariff-exempt regions. Its medical products often benefit from industry-specific exemptions, providing moderate resilience. Past tariffs have had minimal impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Nephros might have Average Resilient.

Nephros  (NAS:NEPH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Nephros Tariff Resilience Score Related Terms

NEPH vs MLSS, RGNT, HBIO: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Nephros's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nephros Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Nephros's Tariff Resilience Score falls into.


NEPH
63GF Score
Nephros Inc NEPH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Nephros (NEPH) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Nephros ranks #75 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 9%.
Is Nephros' Tariff Resilience Score too high?
Nephros' current Tariff Resilience Score is 6. Based on the distribution chart, Nephros ranks #75 out of 836 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Tariff Resilience Score compare to MLSS and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #75 out of 836 companies for Tariff Resilience Score. This places Nephros in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Nephros's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $3.30 — trading 14.6% above its estimated fair value. The current Tariff Resilience Score is 6. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Nephros (NEPH), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.30 is trading 14.6% above its estimated GF Value™ of $2.88. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Tariff Resilience Score: 6
  • GF Value™: $2.88 vs. price of $3.30 (14.6% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price
$2.88
GF Value